Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Greatest Biosimilar Impact May Be Interchangeability Policy, Sandoz Says

This article was originally published in The Pink Sheet Daily

Executive Summary

As the agency and stakeholders gear up for public hearing, Sandoz argues that since Europe has not addressed interchangeability, FDA could step to the forefront by focusing on it as part of implementing the U.S. biosimilar pathway.

You may also be interested in...



Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions

Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.

Biosimilars’ Next Big Hurdle For FDA Could Be Clinician Education

Companies and other groups want clear FDA communication on biosimilars as pharmacists look for an Orange Book-like reference manual to be ready for prescriptions.

Biosimilar Suffix Naming Idea Trips On Dispensing Problem

American Pharmacists Association tells FDA during biosimilar guidance hearing that using suffixes to create unique names will be problematic. FDA may be leaning toward the unique names, saying published literature indicates adequate safety tracking is not possible without them.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel